Stroke Circulatory System
Conditions
Interventions
This will be a prospective biorepository study to evaluate the blood and thrombus collected mechanical thrombectomy procedure. The imaging sub-study will include MRI measures. The imaging substudy is
Sponsors
Cambridge University Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy volunteers: 1. Over 18 years old 2. Able to and provide written informed consent to participate 3. If female, postmenopausal or if women of childbearing potential (WOCBP) using a suitable form of contraception 4. If male, use of a suitable contraceptive method 5. Capable of undergoing a minimum of one study visit Patients: 1. Over 18 years old 2. Attending Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust (including patients transferred from other hospital sites) 3. Patients planning to undergo, or recently having undergone a mechanical thrombectomy procedure for AIS with LVO in Addenbrooke’s Hospital 4. If female, postmenopausal or if of childbearing potential (WOCBP) using a suitable form of contraception 5. If male, use of a suitable contraceptive method
Exclusion criteria
Exclusion criteria: Healthy volunteers and patients. 1. Age less than 18 years. 2. Patients who lack capacity to consent to entry to the study, where the personal consultee or clinical team feel entry into the study is not appropriate. 3. Patients who lack capacity to consent to entry to the study who object to entry into the study, or to study procedures, contrary to section 33 of the Mental Capacity Act 2005. 4. Contraindication or inability to tolerate MRI 5. Pregnant or actively breast-feeding woman 6. If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI safe at 3 T (researcher to confirm) 7. Clinically significant cardiac, pulmonary or neurological diseases as determined by the investigators 8. Laboratory abnormalities that may impact on the study results although no screening will be required for entry into the study. 9. Any other significant medical or psychiatric history rendering the subject ineligible as deemed by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Identification of blood proteomic, metabolomic, and clot inflammatory biomarkers will be carried out using immunofluorescence, immunohistochemistry, the Olink proteomics platform, liquid chromatography–tandem mass spectrometry, and spatial transcriptomics on samples collected from the clot and blood during MT. 2. Identification of imaging biomarkers measured using hyperpolarised C-13 MRI, sodium MRI, DMI, fMRI and MRS within 14 days of MT 3. Clinical outcome will be measured using the TICI (Thrombolysis in Cerebral Infarction) grade, the mRS (modified Rankin Scale) score and the rate of SICH (Symptomatic Intracranial Haemorrhage) up to one year after MT. | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Contacts
Public ContactMarta;Abhishekh Hulegar Wylot;Ashok
;
Outcome results
None listed